[Pubmed] Galcanezumab-Induced Myasthenia Gravis-Like Symptoms
Posté : 10 juil. 2023 12:00
Cureus. 2023 Jun 8;15(6):e40127. doi: 10.7759/cureus.40127. eCollection 2023 Jun.
ABSTRACT
Fluctuating weakness affecting the ocular, bulbar, and/or appendicular muscles is characteristic of myasthenia gravis. Autoimmune components and certain drugs have been implicated in the pathophysiology of this disease. I report a case of chronic migraine in which the patient developed symptoms of myasthenia gravis after using galcanezumab, the recently approved anti-calcitonin gene-related peptide (anti-CGRP). This case shows that anti-CGRP medications could affect the neuromuscular junction and cause such symptoms. Moreover, this case illustrates the clinical approach and management of such a presentation.
PMID:37425560 | PMC:PMC10329417 | DOI:10.7759/cureus.40127
Source: https://pubmed.ncbi.nlm.nih.gov/3742556 ... t6+86293ac